Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to help in the development of safe, effective and
reversible male contraception. We are examining the impact of the drug Miglustat on sperm
production in normal men.
We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
sperm production. We believe Miglustat may have some potential as a safe, reversible male
contraceptive.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)